These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36986637)

  • 21. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
    Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC
    J Nucl Med; 2012 Sep; 53(9):1481-9. PubMed ID: 22851637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimodal Imaging of 2-Cycle PRRT with
    Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
    J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of
    Deiser S; Drexler M; Moreno-Alcántar G; Irl M; Schmidt C; Günther T; Casini A
    Inorg Chem; 2023 Dec; 62(50):20710-20720. PubMed ID: 37556427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, Biodistribution, and Radiation Dosimetry of
    Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3p-C-NETA: A versatile and effective chelator for development of Al
    Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
    Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
    [No Abstract]   [Full Text] [Related]  

  • 26. Design and development of the theranostic pair
    Mansi R; Fani M
    J Labelled Comp Radiopharm; 2019 Aug; 62(10):635-645. PubMed ID: 31112618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships between uptake of [
    Stenvall A; Gustafsson J; Larsson E; Roth D; Sundlöv A; Jönsson L; Hindorf C; Ohlsson T; Sjögreen Gleisner K
    EJNMMI Res; 2022 Dec; 12(1):75. PubMed ID: 36534192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist.
    Abiraj K; Ursillo S; Tamma ML; Rylova SN; Waser B; Constable EC; Fani M; Nicolas GP; Reubi JC; Maecke HR
    EJNMMI Res; 2018 Aug; 8(1):75. PubMed ID: 30069789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications.
    Fersing C; Masurier N; Rubira L; Deshayes E; Lisowski V
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
    Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
    Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
    Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
    Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
    Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.
    Borgna F; Haller S; Rodriguez JMM; Ginj M; Grundler PV; Zeevaart JR; Köster U; Schibli R; van der Meulen NP; Müller C
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1113-1126. PubMed ID: 34625828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of
    Zhang Q; Liu T; Ding J; Zhou N; Yu Z; Ren Y; Qin X; Du P; Yang Z; Zhu H
    Mol Pharm; 2022 Nov; 19(11):4149-4156. PubMed ID: 36198565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.